16
Participants
Start Date
November 9, 2022
Primary Completion Date
March 23, 2026
Study Completion Date
March 23, 2026
Mezagitamab
TAK-079 subcutaneous injection.
National Taiwan University Hospital, Taipei
Semmelweis Egyetem, Budapest
Royal Melbourne Hospital, Parkville
Monash Health, Monash Medical Centre, Clayton
Core Research Group, Milton
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged
Fundacio Puigvert, Barcelona
Ajou University Hospital, Suwon
Taipei Medical University Shuang Ho Hospital, New Taipei City
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia, Brescia
Hospital Universitario Marques de Valdecilla, Santander
NorthShore University HealthSystem, Evanston
Boise Kidney and Hypertension Institute - Frenova, Nampa
Amicis Research Center - Northridge - Nordhoff, Northridge
Beijing Friendship Hospital,Capital Medical University, Beijing
National University Hospital- Singapore, Singapore
Guangdong Provincial Peoples Hospital, Guangzhou
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Kasugai Municipal Hospital, Kasugai-Shi
Fujita Health University Hospital, Toyoake-shi
Hiroshima University Hospital, Hiroshima
Sapporo City General Hospital, Sapporo
Seoul National University Hospital, Seoul
Hospital Universitario Vall d'Hebron - PPDS, Barcelona
Leicester General Hospital, Leicester
Hull Royal Infirmary, Hull
Lead Sponsor
Takeda
INDUSTRY